Founded in 2016 and based in San Diego, California, Locana is an RNA-targeting gene therapy company with a platform technology to address a wide spectrum of human genetic diseases. Locana has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. Locana intends to build a portfolio of therapies that address the root cause of genetic diseases driven by dysfunctional RNA behavior.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/22/19 | $55,000,000 | Series A |
ARCH Venture Partners Google Ventures Lightstone Ventures Temasek UCB | undisclosed |
| 12/14/20 | $100,000,000 | Series B |
Acuta Capital Partners ARCH Venture Partners GV Invus Lightstone Ventures RA Capital Management Temasek UCB Vida Ventures | undisclosed |
